An official website of the United States government
Home
Name
Ruxolitinib
Alternate Names
Jakafi
Jakavi
Ruxolitinib
Abbreviations
None
Category
Chemotherapy
Subcategory
JAK 1 and JAK 2 (Janus Kinase Inhibitor)
NSC Number
None
Primary Site
Histology
Polycythemia vera (PV)
Remarks
September 22, 2021 The FDA approved ruxolitinib (Jakafi) for chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
May 24, 2019: FDA approved ruxolitinib (JAKAFI) for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older
December 4, 2014: Ruxolitinib received FDA approval for treatment of polycythemia vera (PV)
November 16, 2011: Ruxolitinib received FDA approval for treatment of myelofibrosis. It has been designated an Orphan Drug.
May 24, 2019: FDA approved ruxolitinib (JAKAFI) for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older
December 4, 2014: Ruxolitinib received FDA approval for treatment of polycythemia vera (PV)
November 16, 2011: Ruxolitinib received FDA approval for treatment of myelofibrosis. It has been designated an Orphan Drug.
Coding
Please see remarks for additional information
